The VEGF inhibitor vatalanib regulates AD pathology in 5xFAD mice

Autor: Seong Gak Jeon, Hyun-ju Lee, HyunHee Park, Kyung-Min Han, Hyang-Sook Hoe

Publikováno v: Molecular Brain, Vol 13, Iss 1, Pp 1-4 (2020)

Abstract Alzheimer’s disease (AD) is a highly prevalent neurodegenerative disease characterized by Aβ accumulation and tau hyperphosphorylation. Epidemiological evidence for a negative correlation between cancer and AD has led to the proposed use

Externí odkaz: https://doaj.org/article/6316625f6cac48cea72368ed7b9fa49f

Inhibitory Effects of Euphorbia ebracteolata Hayata Extract ECB on Melanoma-Induced Hyperplasia of Blood Vessels in Zebrafish Embryos

Autor: TinChung Leung, Wuliji Ao, Jingfeng Yang, Wenjing Dong, Xinyue Han, Chao Bao, Saijilahu Tai, Wu Dong, Liang Xu, Yuxia Bai

Publikováno v: Evidence-Based Complementary and Alternative Medicine, Vol 2021 (2021)
Evidence-based Complementary and Alternative Medicine : eCAM

Melanoma is a serious malignant form of skin cancer. Euphorbiaceae compound B (ECB, 2,4-dihydroxy-6-methoxy-3-methylacetophenone) is an acetophenone compound that is isolated from Euphorbia ebracteolata Hayata (EEH), an herbaceous perennial, and has

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0d9338caaccd53d99be944f37cf9d9f
https://doi.org/10.1155/2021/5543259

A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors

Autor: Lorelei J. Hanson, Mojun Zhu, James F. Glockner, Yingwei Qi, Grace K. Dy, Alex A. Adjei, Julian R. Molina, Gary A. Croghan, Angelina D. Tan, Michelle Roos

Publikováno v: Investigational New Drugs. 38:1755-1762

Purpose Combining small-molecule inhibitors of different targets was shown to be synergistic in preclinical studies. Testing this concept in clinical trials is, however, daunting due to challenges in toxicity management and efficacy assessment. This

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b15b2ca0aa114e29ccaee02483c1e10
https://doi.org/10.1007/s10637-020-00936-z

Multiparameter Evaluation of the Platelet-Inhibitory Effects of Tyrosine Kinase Inhibitors Used for Cancer Treatment

Autor: Delia I. Fernandez, Alicia Veninga, Johan W. M. Heemskerk, Bibian M. E. Tullemans, Marijke J.E. Kuijpers, Paola E. J. van der Meijden, Johannes A. Eble, Maureen J.B. Aarts

Publikováno v: International Journal of Molecular Sciences, Vol 22, Iss 11199, p 11199 (2021)
International Journal of Molecular Sciences; Volume 22; Issue 20; Pages: 11199
International Journal of Molecular Sciences
International Journal of Molecular Sciences, 22(20):11199. Multidisciplinary Digital Publishing Institute (MDPI)

Current antiplatelet drugs for the treatment of arterial thrombosis often coincide with increased bleeding risk. Several tyrosine kinase inhibitors (TKIs) for cancer treatment inhibit platelet function, with minor reported bleeding symptoms. The aim

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4c720f6cc7d39e64f998ef7a0facd8e
https://doi.org/10.3390/ijms222011199

Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme

Autor: Fathalla Khedr, Khaled El-Adl, Helmy Sakr, Mamdouh M. Ali, Rezk R. Ayyad, Abdel-Ghany A. El-Helby

Publikováno v: Anti-Cancer Agents in Medicinal Chemistry. 18:1184-1196

Background: Extensive studies were reported in the synthesis of several phthalazine derivatives as promising anticancer agents as potent VEGFR-2 inhibitors. Vatalanib (PTK787) was the first anilinophthalazine published derivative as a potent inhibito

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00481d49cd7736f2c917b14fb552c087
https://doi.org/10.2174/1871520618666180412123833